In recent years drug-loaded nanofibers prepared using solution electrospinning methods have been actively studied. However, there are a number of problems connected to their solution electrospinning with respect to medical applications because of the hazards associated with the residual solvents. To avoid the use of solvents in this study we prepared and evaluated drug-loaded polylactide (PLA) fiber webs using a laser-electrospinning (LES) type of a melt electrospinning process. The structures and properties of the obtained drug-loaded PLA fiber webs were evaluated by scanning electron microscopy, fluorescence microscopy, wide-angle X-ray diffraction and UV–vis spectrometry. As shown by the various characterization techniques, we employed LES to prepare PLA nanofiber webs with average fiber diameters of 4.21 and 0.67 μm. Additionally, the webs were loaded with argatroban, a thrombin inhibitor, resulting in amorphous structures for both the argatroban and the PLA matrix. An in-vitro investigation of the drug release behavior of the webs revealed that higher release rates occurred for the fiber samples with the small fiber diameters, particularly in comparison with melt spun fibers with an average diameter of 150 μm. Overall, we expect that the herein described drug-loaded PLA nanofiber webs can be applied as medical materials with drug delivery system functions.

近年来，已经积极研究了使用溶液电纺丝方法制备的载有药物的纳米纤维。然而，由于与残留溶剂有关的危害，在医学应用中，与它们的溶液电纺丝存在许多问题。为避免在这项研究中使用溶剂，我们使用激光静电纺丝（LES）类型的熔融静电纺丝工艺制备并评估了载药聚乳酸（PLA）纤维网。通过扫描电子显微镜，荧光显微镜，广角X射线衍射和UV-vis光谱对获得的载有PLA纤维网的结构和性能进行了评估。如各种表征技术所示，我们使用LES制备了平均纤维直径为4.21和0.67μm的PLA纳米纤维网。另外，腹板上装有凝血酶抑制剂argatroban，导致argatroban和PLA基质均具有非晶态结构。对网的药物释放行为的体外研究表明，纤维直径较小的纤维样品的释放速率更高，特别是与平均直径为150μm的熔纺纤维相比。总体而言，我们希望本文所述的载有药物的PLA纳米纤维网可用作具有药物递送系统功能的医用材料。特别是与平均直径为150μm的熔纺纤维相比。总体而言，我们希望本文所述的载有药物的PLA纳米纤维网可用作具有药物递送系统功能的医用材料。特别是与平均直径为150μm的熔纺纤维相比。总体而言，我们希望本文所述的载有药物的PLA纳米纤维网可用作具有药物递送系统功能的医用材料。